{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:28:05Z","timestamp":1783024085319,"version":"3.54.6"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy with a dismal prognosis and limited responsiveness to conventional therapies. Recent advances in targeted therapy and immunotherapy have shown promise in improving outcomes.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT serves as a valuable tool for evaluating disease extent and monitoring therapeutic response in ATC. We present the case of a 51-year-old woman diagnosed with biopsy-proven anaplastic thyroid carcinoma, presenting with extensive locoregional disease and pulmonary metastases on Pembrolizumab and Lenvatinib.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT was done for response assessment which showed near complete metabolic response.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006207","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:00:25Z","timestamp":1772038825000},"page":"e601-e602","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG PET\/CT Demonstrates Significant Response in Anaplastic Thyroid Carcinoma Treated With Combined Immunotherapy and Targeted Therapy"],"prefix":"10.1097","volume":"51","author":[{"given":"Yamini","family":"Dharmashaktu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritwik","family":"Wakankar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim A.","family":"Shamim","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200301000-00012","article-title":"Anaplastic thyroid cancer","volume":"15","author":"Pasieka","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.oraloncology.2013.03.440","article-title":"Anaplastic thyroid cancer","volume":"49","author":"Neill","year":"2013","journal-title":"Oral Oncol"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1097\/RLU.0b013e3182291d03","article-title":"PET\/CT imaging of thyroid cancer","volume":"36","author":"Mosci","year":"2011","journal-title":"Clin Nucl Med"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"107281","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review","volume":"91","author":"Mo","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"7718","DOI":"10.3390\/curroncol29100610","article-title":"Rationale efficacy and safety evidence of lenvatinib and pembrolizumab association in anaplastic thyroid carcinoma","volume":"29","author":"Boudin","year":"2022","journal-title":"Curr Oncol"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll","year":"2024","journal-title":"BMC Endocr Disord"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:07:01Z","timestamp":1783022821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006207","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}